Effects of cyclosporin A on immune activation markers in patients with active psoriasis

Dermatology

Volumn 199, Issue 2, 1999, Pages 144-148

  Economidou, J ^a,d   Barkis, J ^a   Demetriou, Z ^a   Avgerinou, G ^a   Psarra, K ^b   Degiannis, D ^c   Vareltzidis, A ^a   Katsambas, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c ONASSIS CARDIAC SURGERY CENTER   (Greece)

^d Evangelismos H ^*  (Greece)

Author keywords

Cyclosporin A; Cytokines; Lymphocyte subsets; Psoriasis

Indexed keywords

CD23 ANTIGEN; CD3 ANTIGEN; CYCLOSPORIN A; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NEOPTERIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CYCLOSPORINE; CYTOKINES; DERMATOLOGIC AGENTS; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKINS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPTERIN; PSORIASIS; TH1 CELLS;

EID: 0032725326     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018222     Document Type: Article

References (22)

1. Valdimarsson H, Baker BS, Jonsdottir H, Fry L: Psoriasis - A disease of abnormal proliferation induced by T lymphocytes. Immunol Today 1986;7:256-259.
2. Valdimasrson H, Baker B, Jonsdottir I, Powels A, Fry L: Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens. Immunol Today 1995;16:145-149.
3. Valdimarsson H, Sigmundsdottir H, Jonsdottir I: Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 1997;107(suppl 1):21-24.
4. Chang E, Hammerberg C, Fisher G, Baadsgaard O, Ellis CN, Voorhees JJ, Cooper KD: T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis. Arch Dermatol 1995;128:1479-1485.
5. Bos JD, Kapsenberg BM: The skin immune system: Progress in cutaneous biology. Immunol Today 1993;14:75-78.
6. Wong RL, Winslow CM, Cooper KD: The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14:69-73.
7. Ellis CN, Fradin M, Messana J, Brown MD, Siegel MT, Hartley H, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Madu ME, Duell E, Annesley TM, Cooper KD, Voorhees JJ: Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277-284.
8. Baker BS, Fry L: The immunology of psoriasis. Br J Dermatol 1992;126:1-9.
9. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Buschenfelde KH, Fleiseher B: T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-149.
10. Servitje O, Bordas X, Seron D, Vidaller A, Moreno A, Curco N, Sais G, Peyrv J: Changes in T-cell phenotype and adhesion molecule expression in psorialic lesions after low-dose cyclosporin therapy. J Cutan Pathol 1996;23: 431-436.
11. Olanivan AK, Baker BS, Paige DG, Garioch JJ, Powels AV, Fry L: Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996;288:421-425.
12. Danno K, Kajji A, Mochizuki T: Alterations in ICAM-1 and ELAM-1 expression in psoriatic lesions following various treatments. J Dermatol Sci 1996;13:49-55.
13. Prens EP, van Joost Th, Hegmans JPJJ, 'tHooft-Benne K, Ysselmuiden OE, Benner R: Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. Am Acad Dermatol 1995;33:947-953.
14. Yamamoto T, Kimura K, Katayama I, Koyano T, Mamada A, Miyazaki K, Irimajiri T, Furuse Y, Nishioka K: Beneficial clinical effects of cyclosporin A on severe psoriasis and its dissociation from serum concentrations of soluble interleukin-6 receptor, soluble CD14 antigen, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1. Arch Dermatol Res 1996;289:57-59.
15. de Rie MA, Zonneveld IM, Witkamp L, Van Lier RA, Out TA, Bos JD: Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: A comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol (Stockh) 1996;76:357-360.
16. Trembleau S, Germann T, Gately MK, Adorini L: The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995;16:383.
17. Schopf RE, Naumman S, Rehder M, Morsches B: Soluble intracellular adhesion molecule I levels in patients with psoriasis. Br J Dermatol 1993;128:34-37.
18. Carducci M, Mussi A, Bonifati C, Fazio M, Ameglio F: sICAM-1, sIL-2R, and beta-2 microglobulin serum levels in patients affected with psoriasis: Relationship with disease severity. Arch Dermatol Res 1994;286:420-424.
19. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon gamma. J Exp Med 1984;160:310-316.
20. Fuchs D, Sepp N, Benedikter S, Fritsch P, Wachter H: Immune activation and psoriasis. Lancet 1991;338:759.
21. De Rie M, Hamerlinck F, Bos JD: Neopterin, immune activation and psoriasis. Lancet 1991; 338:1208.
22. Bonnefoy JY, Plater-Zymerk C, Lecoanet-Henchoz S, Gauchat JF, Aubry JP, Graber P: A new role for CD23 in inflammation. Immunol Today 1996;17:418-420.